Previous 10 | Next 10 |
PharmaCyte Biotech ([[PMCB]] +1.9%) has commenced additional physical parameter testing of its CypCaps encapsulated cells for pancreatic cancer, in line with the recommendations provided by the FDA.The FDA has asked that two additional methods be developed to determine the strength ...
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has commenced additional physical parameter testing...
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has successfully completed the nine-months product ...
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has received the clinical hold letter from the U.S....
OTC listed PharmaCyte Biotech sinks ([[PMCB]] -49.2%) after the FDA placed a hold on the company's Investigational New Drug ((IND)) application for a planned Phase 2b trial in locally advanced, inoperable pancreatic cancer. Details on the reason(s) were not disclosed.PharmaCyte’s ...
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has received notification from the U.S. Food and Dr...
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it continues to engage with the U.S. Fo...
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has successfully completed the six-month produ...
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has successfully completed the second Containe...
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has submitted an Investigational New Drug appl...
News, Short Squeeze, Breakout and More Instantly...
PharmaCyte Biotech Inc. Company Name:
PMCB Stock Symbol:
OTCMKTS Market:
PharmaCyte Biotech Inc. Website:
Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”), today announced a $7 mi...